Resmed (RMD) Operating Leases (2019 - 2026)

Resmed has reported Operating Leases for 8 years, with the latest figure at $149.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 8.59% year-over-year to $149.8 million; the trailing twelve-month figure through Mar 2026 stood at $149.8 million (up 8.59% YoY), and the FY2025 full-year result was $153.0 million, up 8.18% from the prior year.
• Operating Leases for Q1 2026 stood at $149.8 million, down from $154.1 million in the prior quarter.
• The five-year high for Operating Leases was $154.1 million in Q4 2025, with the low at $112.4 million in Q3 2023.
• Historically, Operating Leases has averaged $133.4 million across 5 years, with a median of $138.0 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases retreated 12.43% — and 2024, when it advanced 28.49%.
• Resmed's Operating Leases stood at $116.4 million in 2022, then increased by 20.79% to $140.6 million in 2023, then decreased by 1.06% to $139.2 million in 2024, then climbed by 10.76% to $154.1 million in 2025, then fell by 2.79% to $149.8 million in 2026.
• The last three Operating Leases figures came in at $149.8 million (Q1 2026), $154.1 million (Q4 2025), and $147.8 million (Q3 2025), per Business Quant data.